Catalyst Wire Dossier Catalyst Wire Dossier

RDEA3170

RDEA3170 · Ardea Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for RDEA3170, covering 2014-01-09 to 2019-09-24. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia [Phase 2]

See pricing